From: Feasibility of sustained response through long-term dosing in food allergy immunotherapy
Reaction numbers per ITT participant | Total | Month 0–12 | Month 13–24 | Month 25–36 | Month 37–48 | Month 49–72 |
---|---|---|---|---|---|---|
Number of participants followed during time period | 46 | 46 | 46 | 46 | 41 | 23 |
Total reactions per ITT participant median (range) | 25 (0–35) | 15 (0–21) | 5 (0–7) | 2 (0–3) | 0 (0–1) | 0 |
Gastrointestinal | 4 (0–4) | 2 (0–3) | 0 (0–1) | 0 (0–1) | 0 | 0 |
Mild | 2 (0–3) | 1 (0–2) | 0 (0–1) | 0 (0–1) | 0 | 0 |
Moderate | 0 (0–2) | 0 (0–1) | 0 | 0 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 | 0 |
Respiratory/thoracic/mediastinal | 2 (0–6) | 1 (0–4) | 0 (0–1) | 0 (0-1) | 0 | 0 |
Mild | 1 (0–5) | 1 (0–4) | 0 | 0 | 0 | 0 |
Moderate | 0 (0–1) | 0 | 0 (0–1) | 0 (0–1) | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 | 0 |
Skin/subcutaneous | 8 (0–9) | 5 (0–47) | 2 (0–4) | 1 (0–2) | 0 | 0 |
Mild | 7 (0–9) | 4 (0–27) | 1 (0–2) | 1 (0–1) | 0 | 0 |
Moderate | 1 (0–3) | 2 (0–20) | 1 (0–1) | 0 (0–1) | 0 | 0 |
Severe | 0 (0–1) | 0 (0–2) | 0 (0–1) | 0 | 0 | 0 |
Eye | 1 (0–2) | 0 (0–5) | 0 (0–1) | 0 (0–1) | 0 | 0 |
Mild | 1 (0-2) | 0 (0–5) | 0 (0–1) | 0 (0–1) | 0 | 0 |
Moderate | 0 | 0 | 0 | 0 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 | 0 |
Cardiovascular | 0 | 0 | 0 | 0 | 0 | 0 |
Nasal congestion | 6 (0–10) | 3 (0–5) | 2 (0–4) | 1 (0–1) | 0 | 0 |
Mild | 6 (0–10) | 3 (0–5) | 2 (0–4) | 1 (0–1) | 0 | 0 |
Moderate | 0 (0–2) | 0 (0–1) | 0 (0–1) | 0 | 0 | 0 |
Severe | 0 (0–1) | 0 (0–1) | 0 | 0 | 0 | 0 |
Other (i.e. anxiety) | 6 (0–21) | 3 (0–44) | 1 (0–2) | 0 (0–1) | 0 (0–1) | 0 |
Mild | 6 (0-21) | 3 (0–44) | 1 (0–2) | 0 (0–1) | 0 (0–1) | 0 |
Moderate | 0 | 0 | 0 | 0 | 0 | 0 |
Severe | 0 | 0 | 0 | 0 | 0 | 0 |